Intensive Care Unit, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Mol Med Rep. 2013 Apr;7(4):1251-6. doi: 10.3892/mmr.2013.1314. Epub 2013 Feb 7.
The nucleus of the endothelial cell contains large amounts of high-mobility group box protein 1 (HMGB1), a cytokine mediator of inflammation, and the endothelium may be a crucial source of HMGB1 during the inflammatory response. Therefore, the downregulation of HMGB1 expression by RNA interference (RNAi) may decrease inflammatory activity. The aim of this study was to investigate the possible mechanism of action and the effect of HMGB1 on homeobox A9 (HOXA9) and E-selectin expression. Recombinant human full-length HMGB1 was cloned by PCR amplification from human umbilical vein endothelial cells (HUVECs) and then subcloned into a pcDNA‑3.1-myc-his-B vector. Specific short hairpin RNAs (shRNAs) for the HMGB1 target sequence and a scrambled sequence were designed, synthesized and cloned into a pRNA‑U6.1/Neo vector. Specific small interfering RNAs (siRNAs) for the HOXA9 target sequence were commercially prepared and the expression levels of HMGB1, HOXA9, intracellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1) and E-selectin were detected using real-time PCR and western blot analysis. The expression of the full-length HMGB1 gene and protein was verified in HUVECs. The shRNA for HMGB1 and siRNA for HOXA9 successfully decreased the expression levels of HMGB1 and HOXA9, respectively. ICAM1, VCAM1 and E-selectin were downregulated through HMGB1 interference in HUVECs, and HMGB1 shRNA decreased E-selectin expression by HOXA9. These results demonstrated the potential use of specific siRNA targeting HMGB1 expression for the development of novel therapeutic agents for inflammatory disorders.
内皮细胞的核内含有大量高迁移率族蛋白 1(HMGB1),一种炎症的细胞因子介质,内皮细胞在炎症反应中可能是 HMGB1 的重要来源。因此,通过 RNA 干扰(RNAi)下调 HMGB1 的表达可能会降低炎症活性。本研究旨在探讨 HMGB1 对同源盒 A9(HOXA9)和 E-选择素表达的可能作用机制及影响。通过从人脐静脉内皮细胞(HUVEC)中 PCR 扩增克隆重组人全长 HMGB1,然后将其亚克隆到 pcDNA-3.1-myc-his-B 载体中。针对 HMGB1 靶序列和乱序序列设计、合成并克隆特异性短发夹 RNA(shRNA)到 pRNA-U6.1/Neo 载体中。针对 HOXA9 靶序列的特异性小干扰 RNA(siRNA)由商业制备,并使用实时 PCR 和 Western blot 分析检测 HMGB1、HOXA9、细胞间黏附分子 1(ICAM1)、血管细胞黏附分子 1(VCAM1)和 E-选择素的表达水平。在 HUVEC 中验证了全长 HMGB1 基因和蛋白的表达。HMGB1 的 shRNA 和 HOXA9 的 siRNA 分别成功降低了 HMGB1 和 HOXA9 的表达水平。通过 HMGB1 干扰,HUVEC 中的 ICAM1、VCAM1 和 E-选择素表达下调,HMGB1 shRNA 通过 HOXA9 降低了 E-选择素的表达。这些结果表明,针对 HMGB1 表达的特异性 siRNA 具有开发新型炎症性疾病治疗药物的潜力。